enteral nutrition

Phase 3Small molecule

JJagiellonian University

enteral nutrition is one of 88 small molecule programs targeting Esophageal Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal CarcinomaActive, not recruiting

Iron Deficiency AnemiaActive, not recruiting

PterygiumActive, not recruiting

Esophageal CarcinomaPhase 3

Active, not recruiting

Iron Deficiency AnemiaPreclinical

Active, not recruiting

PterygiumPreclinical

Active, not recruiting

Competition

Competitive Landscape

85 competitors in Iron Deficiency Anemia

#DrugCompanyPhaseTrials

Venofer

AAmerican Regent, Inc.

Phase 3

7 2

Dexferrum

NNew River Pharmaceuticals

Phase 3

2 3

Auryxia

KKeryx Biopharmaceuticals

Phase 3

1 4

Iron

WWatson Pharmaceuticals

Phase 3

5 5

IV Iron

Pfizer

Phase 3

—6

Standard Medical Care

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Phase 3

2 7

Iron Sulphate

PPierre Fabre Pharma GmbH

Phase 3

1 8

Ferrous Sulphate

VVifor Pharma

Phase 3

1 9

Ferrous Fumarate Tab

AAin Shams University

Approved

2 10

enteral nutrition

JJagiellonian University

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Active, not recruiting

Crohn's Disease

NCT06673134

Clinical

Trials by Indication[1]

Iron deficiency anemia1 trial

Oxidative Stress and Inflammation Caused by Intravenous Iron in Crohn's Disease Patients With Iron Deficiency Anemia

Completed·JJinling Hospital, China·N/A·NCT01823029·387 enrolled

Esophageal Carcinoma1 trial

Chemoradiotherapy With or Without Enteral Nutrition for Locally Advanced Thoracic Esophageal Carcinoma

Completed·SSichuan Cancer Hospital and Research Institute·Phase 3·NCT02399306·222 enrolled

Crohn's Disease1 trial

Prospective Cohort Establishment and Clinical Observation of Children With Crohn's Disease

Active, not recruiting·TTongji Hospital··NCT06673134·100 enrolled

Gastroesophageal Reflux1 trial

Health, Economic Analysis and Clinical Aspects of Patients With Neurological Disabilities in Enteral Nutrition With Dedicated Formula. The Role of Nissen's Fundoplication in the Management of Gastroesophageal Reflux

Unknown status·—··NCT05068089·360 enrolled

Pterygium1 trial

Efficacy Study of Tripterygium Glycoside Combined With Enteral Nutrition in the Treatment of Crohn's Disease for Induction Remission

Unknown status·ZZhu Weiming·N/A·NCT01820247·100 enrolled

1 more indication

Pancreatic Fistula1 trial

Enteral Nutrition in the Treatment of Pancreatic Fistulas - A Prospective Study

Completed·JJagiellonian University·Phase 4·NCT01025414·78 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for enteral nutrition. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — enteral nutrition compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for enteral nutrition. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jagiellonian University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: JJagiellonian University

enteral nutrition

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Iron deficiency anemia1 trial

Esophageal Carcinoma1 trial

Crohn's Disease1 trial

Gastroesophageal Reflux1 trial

Pterygium1 trial

Pancreatic Fistula1 trial

References

Drug Info

Quick Facts

Related News